[Multicenter study of fluconazole in the treatment of oropharyngeal candidiasis in immunodepressed patients].
We have evaluated the efficacy of fluconazole, 50 mg/day for 2 weeks, to treat oropharyngeal candidiasis in immunologically compromised patients. There were overall 27 patients, 25 of which were HIV+ and 2 had neutropenia. The rate of clinical response at the end of therapy, and one week and one month afterwards were 96%, 76% and 64%, respectively. The microbiological eradication was achieved in 36% of patients. The tolerance of the drug was satisfactory, although in 3 cases features of hepatic toxicity were detected. The convenience, good tolerance and clinical efficacy of fluconazole make it the therapy of choice for oropharyngeal candidiasis in immunologically compromised patients.
Muñoz
P
P
Servicio de Microbiología Clínica, Hospital General Gregorio Marañón, Madrid.
Moreno
S
S
Garau
X
X
López Bernaldo de Quirós
J C
JC
Berenguer
J
J
More
J
J
Bouza
E
E
D000328:Adult; D002180:Candidiasis, Oral / Q000150:complications / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications; D011446:Prospective Studies
D015725:Fluconazole
Estudio multicéntrico de fluconazol en el tratamiento de la candidiasis orofaríngea en pacientes inmunodeprimidos.